Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07239778 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The PEDAL Intervention - Reducing Affective Lability in Bipolar Disorder

Study acronym: PEDAL
StatusRecruiting
PhasePhase 2
Started2025-12-01
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Jun 30, 2026 → Dec 30, 2026
See other at-risk trials from Oslo University Hospital

Amendment history

2026-09-03
critical
Study Status, Contacts/Locations v2
Recruitment opened
Primary completion pushed: 2026-06-30 → 2026-12-30
Completion pushed: 2026-12 → 2027-06
Start dateestimated 2025-11-25→confirmed 2025-12-01
Study sitesdetails revised at 4 of 4 sites
2025-11-20
minor
Study Identification, Study Status, Study Description, Arms and Interventions, Outcome Measures v1
Secondary endpointsdetails revised at 7 of 7 entries
Study description+7 characters
Bipolar disorder (BD) is a severe mental illness with largesignificant costs for the affected individuals, their families, and soc [...] eutic elements. Its main purpose is to facilitate a learning- and developmental process for the patient, in order to enab [...] se to Oslo will participate, covering a total population of close toapproximately 740.000. We aim to recruit 120 patients with BD to the trial. AL is defined as rapid, excessive, and unpredictable shifts in affective states, is common in [...] ital tools align well with the objectives of psychoeducation, and such tools are increasingly used to enhance i [...] [...]
Study title-32 characters
The PEDAL Intervention - Reducing Affective Lability in Bipolar Disorder - a Randomised Controlled Trial
2025-11-16
minor
Original filing
PEDAL is a group-based intervention for patients with bipolar disorder that builds on the traditional group psychoeducational program (GPP) by adding digital tools and specific strategies to help manage rapid fluctuations between affective states, known as affective lability. The program's goal is to help patients learn and develop new ways to better manage their condition, with particular attention to affective lability and other difficulties with affect regulation- challenges which are not typically addressed in current treatments. The PEDAL trial will run at five clinical sites around Oslo and Vestre Viken, aiming to recruit 120 participants with bipolar disorder. The program combines existing group sessions from GPP with new components: additional group sessions focusing on strategies for improving affect regulation such as mindfulness and distress tolerance, an online platform with all course materials including instructional videos and other resources, and an app-based mood diary. This framework maintains the benefits of regular group meetings while adding digital support tools to make the intervention more personalized and accessible. The main aim of PEDAL is to see if the new program reduces affective lability more effectively than GPP (treatment-as-usual; TAU), and both intervention groups will be compared on the level of affective lability before and after the intervention. Several secondary outcomes like mood symptoms, suicidal thoughts, perceived stress, and quality of life will also be assessed. In terms of study design, all study sites will run the PEDAL and TAU groups in parallel, and participants will be randomly assigned to either PEDAL or TAU. To qualify for the study, participants must be aged 18-65, diagnosed with bipolar disorder, able to participate in a group intervention, capable of providing informed consent, and have a smartphone or computer. People who have previously completed group psychoeducation, who are unable to complete the study period due to pregnancy or other factors, or those who cannot use the required technology are excluded. In summary, PEDAL is a novel study that modernizes the existing group psychoeducational program for bipolar disorder by targeting affective lability through skills training and digital tools, while also evaluating its reception and effects in a controlled clinical trial.
Trial Details
NCT Number NCT07239778
Lead Sponsor Oslo University Hospital
Collaborators: Vestre Viken Hospital Trust, Diakonhjemmet Hospital, Lovisenberg Diakonale Hospital
Conditions Bipolar Disorder (BD)
Enrollment 120 participants
Start Date 2025-12-01
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-09-04